Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at JPMorgan NAPA Valley Forum (Virtual) Transcript

Mar 29, 2021 / 08:00PM GMT
Release Date Price: $44.96 (+4.68%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Thanks, everyone, for joining us. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing our virtual Napa Valley Biotech Forum with Ionis today. I'm joined by the company's CEO (sic) [CFO], Beth Hougen.

Questions & Answers

Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

So maybe we can get right into it. Since Brett became CEO last year, the company has evolved its strategy and is now planning to commercialize some of its wholly owned medicines independently. So what's Ionis' strategy on which drugs it's going to commercialize? And do you still plan to partner some programs? And how will you decide?

Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Great. Thanks, Jess, and thank you for having us. We're happy to be here this afternoon. It's a great question, and we're so excited about the future of the company right now with such a deep

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot